Merus NV to Present at BofA Securities 2025 Health Care Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 — Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company, has announced that Dr. Bill Lundberg, President and Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference. The event is scheduled for Thursday, May 15, 2025, at 8:40 a.m. PT/11:40 a.m. ET. This presentation will provide insights into Merus’ innovative work in developing bispecific antibody therapeutics, specifically their Biclonics® and Triclonics® technologies.

Financial Update and Business Outlook

On May 7, 2025, Merus announced its financial results for the first quarter of 2025. The company highlighted ongoing clinical trials, including a phase 2 trial of Petosemtamab in combination with pembrolizumab for 1L PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). Merus plans to provide an update on clinical data at the 2025 ASCO® Annual Meeting.

Merus’ current operating plan, supported by existing cash, cash equivalents, and marketable securities, is expected to fund the company’s operations through 2028. This financial stability underscores the company’s commitment to advancing its pipeline and achieving its mission to treat and cure cancer patients.

Company Overview

Merus NV, headquartered in Utrecht, Netherlands, operates in the biotechnology sector within the health care industry. The company is listed on the Frankfurt Stock Exchange, with its shares traded in EUR. As of May 7, 2025, Merus’ close price was 33.2 EUR, with a 52-week high of 55.5 EUR on June 27, 2024, and a 52-week low of 29.4 EUR on April 9, 2025. The company’s market capitalization stands at 2.89 billion EUR, and it has a price-to-earnings ratio of -13.7, reflecting its current financial performance and market position.

For more information about Merus NV and its innovative therapeutic developments, visit their website at www.merus.nl .